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Abstract
Background: Given the complexity of surgical care, perioperative patients are at high risk of opioid-related adverse
drug events. Existing methods of detection, such as trigger tools and manual chart review, are time-intensive which makes
sustainability challenging. Using strategic rule design, computerized surveillance may be an efficient, pharmacist-driven
model for event detection that leverages existing staff resources.
Methods: Computerized adverse drug event surveillance uses a logic-based rules engine to identify potential adverse
drug events or evolving unsafe clinical conditions. We extended an inpatient rule (administration of naloxone) to detect
opioid-related oversedation and respiratory depression to perioperative care at a large academic medical center. Our
primary endpoint was the adverse drug event rate. For all patients with a naloxone alert, manual chart review was
performed by a perioperative clinical pharmacist to assess patient harm. In patients with confirmed oversedation, other
patient safety event databases were queried to determine if they could detect duplicate, prior, or subsequent opioid-
related events.
Results: We identified 419 cases of perioperative naloxone administration. Of these, 101 were given postoperatively
and 69 were confirmed as adverse drug events after chart review yielding a rate of 1.89 adverse drug events/1000 surgical
encounters across both the inpatient and ambulatory settings. Our ability to detect inpatient opioid adverse drug events
increased 22.7% by expanding surveillance into perioperative care. Analysis of historical surveillance data as well as a
voluntary reporting database revealed that 11 of our perioperative patients had prior or subsequent harmful
oversedation. Nine of these cases received intraoperative naloxone, and 2 had received naloxone in the post-anesthesia
care unit. Pharmacist effort was approximately 3 hours per week to evaluate naloxone alerts and confirm adverse drug
events.
Conclusion:  A small investment of resources into a pharmacist-driven surveillance model gave great gains in
organizational adverse drug event detection. The patients who experienced multiple events are particularly relevant to
future studies seeking risk factors for opioid induced respiratory depression. Computerized surveillance is an efficient,
impactful, and sustainable model for ongoing capture and analysis of these rare, but potentially serious events.
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Background
Perioperative care exists in a unique, highly complex envi-
ronment comprised of preoperative screening, same day
surgery, preoperative holding areas, operating rooms, and
post-anesthesia care units (PACUs). Patient care is deliv-
ered by multidisciplinary teams, involves high cost, and
utilizes sophisticated technologies that may have interop-
erability constraints [1,2]. The combination of these char-
acteristics in such a fragmented environment creates high
risk for medication-related harm [3]. Adverse drug events
(ADEs) are defined as any injury resulting from medical
interventions related to a drug, and they have been impli-
cated in both increasing costs and length of stay within
the surgical population [4]. It has been shown that inpa-
tient clinical pharmacists' presence on care units can have
a direct impact on increasing ADE discovery in critical care
and pediatric settings [5,6]. Since much of the harm to
surgical patients has been attributed to the lack of compre-
hensive oversight of high risk medications, the United
States Pharmacopeia has recommended, and Duke has
implemented, allocation of a dedicated pharmacist to the
post-anesthesia care unit in order to oversee the distribu-
tion of medications [3].
Many models have been deployed to detect instances of
medication-related harm in the surgical population. One
study focused on opioid oversedation events found by ret-
rospective chart review. They implemented successful
strategies to reduce the incidence of these ADEs, but
found it difficult to sustain improvements due to the lack
of dedicated resources [7]. Another study used a struc-
tured survey tool of multiple open-ended questions
administered to anesthesiologists. Trained examiners
interviewed anesthesiologists in the PACU to elicit cap-
ture of non-routine events that may have caused patient
harm. They concluded this methodology can detect a
higher incidence of patient injury than chart review alone,
and may be an effective strategy to complement voluntary
reporting in anesthesia quality improvement (QI) [8].
Trigger tool methodology is designed for retrospective
review of a random sample of patient charts using a list of
"triggers," or rule sets. This targeted chart review stream-
lines effort by prompting the reviewer to seek specific
indicators of care-induced injury. The Institute for Health-
care Improvement (IHI) developed a 28-trigger tool for
surgical patients and described its use across 11 hospitals
[9]. This tool has medication specific triggers, one involv-
ing the use of naloxone, and the results revealed that of
138 adverse events (AEs) identified in 125 patient records,
6 were opioid related. The authors concluded that the IHI
surgical trigger tool is a useful methodology for detecting
AEs in surgical patients and may serve as the basis for esti-
mating AE rates that can be used to determine the impact
of surgically-focused interventions.
Similarly, computerized ADE surveillance expands upon
the trigger tool concept by using a computer program to
query a hospital's clinical information system for a com-
bination of characteristics that may indicate the occur-
rence of an ADE. Since a computer provides the first pass,
manual chart review need only be performed for the
potential events, thereby saving significant time over the
traditional trigger tool method. Computerized surveil-
lance technology has been implemented for both inpa-
tient and ambulatory ADE detection and has shown
promising results [10-12]. Although one study has used
this methodology in the surgical inpatient population, we
are unaware of any effort to deploy computerized surveil-
lance across the perioperative continuum of care [13].
Methods
Study design
We performed a retrospective, cross-sectional study that
included all surgical visits from 10/15/2007–10/15/2008
at Duke University Hospital (DUH). DUH perioperative
care includes an inpatient/ambulatory center that con-
tains 31 operating rooms (ORs), a preoperative and post-
anesthesia care unit (PACU), an eye center with 6 ORs,
and an ambulatory surgery center with 9 ORs. For the pur-
poses of this study, we defined a surgical encounter as a
single surgical case in an OR that may include one or more
associated procedures. Although opioid medications are
administered in several perioperative settings, the focus of
our evaluation of patient harm was on postoperative
oversedation since it is where clinical documentation is
most complete. This study was approved by the Duke Uni-
versity Health System Institutional Review Board.
Data collection
The computerized ADE surveillance (ADE-S) system is an
internally developed application that evaluates inpatient
medication, laboratory, and patient demographic infor-
mation against a set of clinical rules to alert for potential
ADEs or evolving unsafe conditions. Technical details of
the system have been discussed in depth in prior publica-
tions [14,15]. Rules indicating situations requiring further
evaluation include alerts for toxic serum drug levels,
nephrotoxic medications and rising serum creatinine lev-
els, or the administration of antidotes such as naloxone.
Nearly 130 rules have been deployed since the system's
inception (12/1/2004) to detect inpatient events. ADE-S
delivers an electronic, daily report that details all triggers
fired, which are then evaluated by clinical pharmacists for
causality according to the method of Naranjo, and severity
using the published Duke University Health System 7-
point scale to ensure they are true instances of harm [16-
18].
On 10/15/2007, we added a rule that fires an alert upon
administration of naloxone within a perioperative loca-Patient Safety in Surgery 2009, 3:18 http://www.pssjournal.com/content/3/1/18
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tion. This information is found within the DUH surgical
information system and is manually entered into an elec-
tronic anesthesia information system (Innovian [Drager,
Telford, PA]) by anesthesia care providers and PACU
nurses. Evaluation of the alerts within the ADE-S database
(Figure 1) was incorporated to the daily workflow of an
existing full time clinical pharmacist, who kept a daily log
of time spent on the project. We defined an adverse event
as 'an injury resulting from medical intervention related
to a drug' [19]. The clinical pharmacist was trained to eval-
uate opioid-related oversedation events by the original
developers of surveillance at DUH. This evaluation
included an assessment of dosing, clinical monitoring of
the patient, objective evidence of oversedation or respira-
tory depression, contributing medications, response to
reversal with naloxone, assessment of alternative causes
and risk factors, and the clinical outcome of the patient.
We did not examine cases of the intraoperative use of
naloxone in patients slow to emerge from anesthesia since
usage is based on the clinical judgment of the anesthesiol-
ogist and the rationale was generally poorly documented
in the anesthesia information system.
Data analysis
Our primary endpoint is the ADE rate calculated as the
number of ADE's per 1000 surgical encounters. The posi-
tive predictive value (PPV) of the naloxone alert was
defined as the percentage of trigger alerts that resulted in
an ADE. This is an established performance metric for the
trigger [16]. As in most surveillance studies, sensitivity was
not calculated as it was not feasible to perform the large
number of chart reviews required to determine if there
were oversedation events in patients who did not have
alerts [16]. We performed a sub-analysis on inpatient and
ambulatory surgical events where the respective rates were
directly compared.
For those patients that were either a) administered intra-
operative naloxone or b) had an ADE in PACU, we cross-
referenced the surveillance (12/1/2006–11/5/2008) and
voluntary incident reporting (4/1/2002–11/5/2008) data-
bases to seek prior or subsequent instances of opioid-
related harm. The voluntary reporting system permits
website entry of any safety incident perceived by DUH
staff.
Results
From 10/15/2007–10/15/2008, 419 cases of naloxone
administration across 36,533 DUH surgical encounters
(15,993 inpatient and 20,940 ambulatory) were detected
by the perioperative naloxone rule (Figure 2). Intraopera-
tive naloxone administration accounted for 318 alerts
which were not evaluated further. The remaining 101
alerts were indicative of naloxone administration in the
post-operative period. These patient populations were
mutually exclusive. Upon chart review of the post opera-
tive naloxone administration alerts, 69 were found to be
ADEs due to perioperative opioid usage. The most com-
mon agents administered intraoperatively were fentanyl
and hydromorphone. The overall PPV of the alert in the
postoperative patients was 68.3% (69/101). Pharmacist
effort was 3 hours/week based on a log maintained by the
pharmacist.
The overall perioperative ADE rate was 1.89 ADEs/1000
surgical encounters (69/36,533). Fifty-three of the 69
ADEs occurred in inpatients, giving a rate of 3.3 ADEs/
1000 inpatient surgical encounters (53/15,933). During
this time, the overall inpatient DUH naloxone computer-
ized surveillance rule detected 6.8 ADEs/1000 opioid-
exposed patient encounters. Expanding detection into
perioperative care therefore increased the number of dis-
covered inpatient ADEs by 22.7%. Sixteen of the 69 post-
operative ADEs occurred during ambulatory surgical
procedures giving a rate of 0.76 ADEs/1000 ambulatory
surgical encounters (16/20,940). Thirteen of the 16
ambulatory surgery patients who experienced ADEs post-
operatively were subsequently discharged after the ADE
resolved. Three ambulatory surgery patients were subse-
quently admitted due to surgical factors unrelated to the
opioid ADE.
Of the 32 alerts for postoperative naloxone use that were
not deemed as ADEs, 5 did indeed indicate patient harm
but the ill effects were not sufficiently associated with an
opioid to be considered an ADE in this study. Of the
remaining 27 alerts, 3 cases had insufficient objective evi-
dence of patient harm in the electronic health record, 13
were naloxone infusions for pruritus, and 11 were low-
dose naloxone infusions for other clinical indications.
Although some of these events may have been considered
ADEs by a broader definition of causality, none were con-
sidered opioid-induced oversedation or respiratory
depression.
For all patients receiving a naloxone trigger alert, we
searched the ADE surveillance and voluntary reporting
databases for either historical or subsequent opioid ADE
history. This identified 11 unique cases of repeated harm-
ful oversedation/respiratory depression in patients who
received naloxone identified by the new surveillance rule
(Table 1). Only one of these cases, however, was detected
by voluntary reporting. Of all 11 subsequent opioid-
related events, 6 occurred during the same hospital admis-
sion, 3 events occurred in a prior admission, and two
occurred in a subsequent admission. Interestingly, the
patient population that received intraoperative naloxone
had a higher number of prior and subsequent events
across these patient safety databases.Patient Safety in Surgery 2009, 3:18 http://www.pssjournal.com/content/3/1/18
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Perioperative adverse drug event surveillance workflow Figure 1
Perioperative adverse drug event surveillance workflow. Patient demographic information and surgical information sys-
tem extracts are processed by the computerized surveillance rules engine. When trigger logic is met, results are populated in 
the adverse drug event surveillance (ADE-S) database. Patient charts and electronic medical record information are reviewed 
daily by a designated perioperative clinical pharmacist who then documents the details of the ADE in a clinical narrative within 
the ADE-S database. These completed evaluations are reviewed and scored by another clinical pharmacist for both causality 
and severity. Reports are generated for clinically-relevant analysis and quality improvement purposes.Patient Safety in Surgery 2009, 3:18 http://www.pssjournal.com/content/3/1/18
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Discussion
Multiple methodologies have been used to quantify
adverse drug events in the perioperative period including
voluntary reporting systems, manual chart review, and
trigger tools. These methods are often retrospective,
resource intensive, and require highly-trained reviewers. A
multi-center perioperative safety initiative that used the
IHI surgical trigger tool illustrated that narcotic-related
harm constituted 6 of the 138 adverse events identified
from 854 patient record reviews (0.7/100 patient records)
[9]. Another retrospective study that identified potential
harm based on naloxone use and manual chart review
reported a baseline oversedation rate of approximately 2
ADE's/1000 postoperative surgical patient discharges and
required 20 hrs/week of clinical pharmacist effort [7].
Using targeted computerized detection methodology, we
Opioid-related ADE rates in perioperative care Figure 2
Opioid-related ADE rates in perioperative care. 419 Naloxone alerts in 36,533 surgical encounters are either due to 
intraoperative naloxone (318) or postoperative (101) post anesthesia care unit (PACU) usage. Of the 101 PACU cases, 69 
were determined to be ADE's. ADE rates are further subdivided by inpatient and ambulatory subgroups.Patient Safety in Surgery 2009, 3:18 http://www.pssjournal.com/content/3/1/18
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identified 3.3 ADEs/1000 surgical inpatient encounters
with 3 hours/week effort. An inpatient study that used
automated dispensing system charges for naloxone com-
bined with targeted chart review demonstrated a PPV of
87% for this type of alert [20]. Our reported PPV was
68.3% in the postoperative population based on
naloxone administration rather than dispensing. The dif-
ference in PPV may be attributable to a broader definition
of an ADE compared to our focus only on oversedation/
respiratory depression. In our review of the literature, we
could not find any studies where the rate of opioid-related
ambulatory ADEs was measured. Our ambulatory rate of
0.76 ADE's/1000 encounters is far less than the inpatient
rate of 3.5 ADE's/1000 encounters, which may be reflec-
tive of the differences in the types of procedures per-
formed, patients' comorbid conditions, acuity of
presentation or other unidentified factors. We have
expanded computerized ADE detection to reliably detect
opioid-related oversedation in both the inpatient and
ambulatory perioperative environment.
Sustainability of perioperative event detection is attribut-
able to the incorporation of event evaluations into routine
clinical pharmacist workflow. By expanding our method-
ology to the entire perioperative patient population, we
were able to improve the overall detection of adverse
events and compare surgical inpatients to overall inpa-
tients. Our effort to cross reference other sources of ADE
data supports the concept of using a broad approach to
improve capture of events as part of an overall quality
improvement strategy [21]. This study has also identified
a subpopulation of patients that are of particular clinical
interest – those that experience repeat incidences of
oversedation. This subset of patients who experience
repeated harmful events is important because it reveals
that there may be underlying factors predisposing these
patients to harm that have yet to be identified, and may
require a more in-depth risk factor analysis. We are con-
sidering adding an alert to the patient's electronic health
record that would signal if that patient has had a history
of opiate-related ADEs and extra caution is necessary in
drug dosage and monitoring. This may help prevent
future ADEs.
There are several limitations to this study. In order for the
computerized surveillance rule engine to detect naloxone
administration, it must have been manually entered into
the DUH anesthesia information system. Therefore, there
is a remote chance that naloxone administration was not
documented and a small number of alerts may have been
missed. The ability to replicate the technical development
of sophisticated computerized adverse drug event surveil-
lance may not be readily transferable to other health sys-
tems, however vended systems are currently available.
Additionally, we have chosen to focus only on a rare yet
serious ADE due to opioids, although the trigger alert does
potentially identify other types of ADEs. Patients most
commonly received fentanyl or hydromorphone, but also
received several other non-opioid medications with seda-
tive effects. We did not analyze other potential ADE cate-
gories, such as the 13 trigger alerts due to naloxone
infusions for pruritus or the 11 alerts for low-dose
naloxone infusions to accompany other indications (e.g.
patient controlled analgesia or epidurals). Finally, we did
not evaluate the cases of intraoperative naloxone use
more closely due to the lack documentation of the ration-
ale for the administration of naloxone in the anesthesia
information system.
Future work is needed to explore contributing factors for
the oversedation cases both postoperatively as well as in
the subpopulation of patients who received intraoperative
naloxone. Since the intraoperative patients experienced a
higher number of subsequent events, they are of particular
interest. This may include the development of a predictive
risk model or pharmacogenomic screening that could be
used to spur intervention strategies that prevent events or
at least their repetition [22]. As we implement quality
improvement initiatives, such as special signaling for
patients with a known history of oversedation, improved
hand-off communications, increased monitoring for any-
one experiencing an ADE postoperatively, and use of
adjunctive opioid sparing non-sedating medications, we
can use the computerized surveillance ADE rate as a quan-
titative measure to track longitudinal improvements. It is
our hope that as electronic health records become main-
stream that adverse drug event detection will evolve to cre-
Table 1: Repeat Opioid-related ADEs in patients identified by a perioperative naloxone trigger
ADE by Perioperative area Same admission, Subsequent 
event
Prior Admission Subsequent Admission Total Repeat Events
Intra-operative Naloxone 5 2 2 9
Post-Operative Naloxone 1 1 [a] 0 2
Total 6 3 2 11
[a] found by voluntary reporting systemPatient Safety in Surgery 2009, 3:18 http://www.pssjournal.com/content/3/1/18
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ative point of care alerting and models will shift from
detection toward mitigation of patient harm.
Conclusion
ADE detection, evaluation, and analysis require consider-
able time, highly trained reviewers, and can be difficult to
sustain long term. Success in this area depends on a relia-
ble detection methodology, efficient incorporation into
staff workflow, and ongoing measurement to differentiate
short term benefits from sustained improvements. Our
academic medical center has effectively leveraged an exist-
ing inpatient computerized ADE surveillance system and
a dedicated perioperative clinical pharmacist to detect and
evaluate perioperative adverse events. By expanding ADE
detection to the immediate perioperative period using this
pharmacist-driven model and focusing on the rare but
serious event of opioid-related oversedation/respiratory
depression, we have demonstrated a quantitative and sus-
tainable model for improved ADE detection in surgical
patients. We have further identified that intraoperative
use of naloxone, and patients who experience repeat
adverse events are areas in need of further investigation as
we strive to improve the safety profile of our health sys-
tem.
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